WJNS  Vol.3 No.4 , November 2013
Central and peripheral neurological involvement in monoclonal gammopathies of undetermined significance

Several studies have suggested a pathogenetic role of paraproteinaemias in PNS damage. Over the few last years, the presence of symptomatic or subclinical PNS lesions in CNS diseases like multiple sclerosis has been described. On the other hand, CNS demyelinating lesions and cervical atrophy have been re- ported in patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Very few cases of MGUS associated with CNS disease alone or with both CNS and PNS disease have been re- ported. Since 1999, we have been studying 16 patients (8 M, 8 F), with a mean age 60.2 ± 13.4, affected by MGUS associated with symptomatic neurological central and/or peripheral diseases. Patients affected with lymphomas, lupus erithematosus and other immunological diseases were excluded. Involvement of both PNS and CNS was not associated to a particular type of paraproteinemia: monoclonal IgM were found in 8 patients; monoclonal IgG in 6 patients and mono- clonal IgA in 1 patient and Igl in 1 patient. High anti- nervous system autoantibodies were found in 10/16 patients and antiMAG antibodies were detected in patients with paraproteinemic demyelinating neuropathy (PDN). High reactivity anti-nervous system might support the hypothesis of a pathogenetic role of MGUS in these neurological diseases. Nevertheless, at present, we cannot exclude that there is only a circumstantial association between MGUS and neurological damages, particularly concerning CNS.

Cite this paper
Galiè, E. , Acqua, M. , Maschio, M. , Koudriavtseva, T. , Marco, E. and Jandolo, B. (2013) Central and peripheral neurological involvement in monoclonal gammopathies of undetermined significance. World Journal of Neuroscience, 3, 282-286. doi: 10.4236/wjns.2013.34038.
[1]   Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guidelines on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First revision. Journal of the Peripheral Nervous System, 15, 185-195.

[2]   Busby, M. and Donaghy, M. (2003) Chronic dysimmune neuropathy, a subclassification based upon the clinical features of 102 patients. Journal of Neurology, 250, 714-724. http://dx.doi.org/10.1007/s00415-003-1068-2

[3]   Chassande, B. and Leger, J.M. (1993) Neurological manifestations of monoclonal gammopathies. Revue du Praticien, 43, 314-316.

[4]   Drappatz, J. and Batchelor, T. (2004) Neurological complications of plasma cell disorders. Clinical Lymphoma, 5, 163-171. http://dx.doi.org/10.3816/CLM.2004.n.022

[5]   Ponsford, S., Willison, H., Veitch, J., Morris, R. and Thomas, P.K. (2000) Long-term clinical and neurophysiological follow-up of patients with peripheral neuropathy associated with benign monoclonal gammopathy. Muscle Nerve, 23, 164-174.

[6]   Uldry, P.A., Steck, F. and Regli, F. (1984) Manifestations neurologiques des gammapathies monoclonales. Schweizerische Medizinische Wochenschrift, 114, 1678-1685.

[7]   Silberman, J. and Lonial, S. (2008) Review of peripheral neuropathy in plasma cell disorders. Hematological Oncology, 26, 55-65. http://dx.doi.org/10.1002/hon.845

[8]   Merkies, I.S. and Faber, C.G. (2012) Fatigue in immunemediated neuropathies. Neuromuscular Disorders, 22, 203-207.

[9]   Galiè, E., Maschio, M. and Jandolo, B. (2005) Cerebellar atrophy and monoclonal gammopathy of undetermined significance: A possible correlation? Journal of Experimental & Clinical Cancer Research, 24, 483-485.

[10]   Rentzos, M., Michalopoulu, M., Gotosidis, K., Caponi, A., Bonakis, A., Kilidireas, K. and Nikolaou, C. (2004) Unusual association of multiple sclerosis with monoclonal gammopathy of undetermined significance (MGUS): Two cases. Functional Neurology, 19, 253-256.

[11]   Galiè, E., Pietrangeli, A., Maschio, M., Pace, A., Vidiri, A., Carosi, M. and Jandolo, B. (2003) Demyelinating disease in monoclonal gammopathy of undeterminated significance. Journal of Experimental & Clinical Cancer Research, 22, 337-339.

[12]   Trèfouret, S., Azulay, J.-Ph, Pouget, J., Boucraut, J. and Serratrice, G. (1996) Sclerose en plaques tardive et gammapathie monoclonal sérique: Association fortuite? Revista de Neurología, 152, 554-556.

[13]   Cai, Z., Blumberg, P.C., Koblar, S.A., Kathy, C., Manavis, J., Ghabriel, M.N. and Thompson, P.D. (2004) Peripheral nervous system and central nervous system pathology in rapidly progressive lower motor neuron syndrome with immunoglobulin M anti GM1 ganglioside antibody. Journal of the Peripheral Nervous System, 9, 79-91. http://dx.doi.org/10.1111/j.1085-9489.2004.009206.x

[14]   Leger, J.M., Younes-Chennoufi, A..B., Zuber, M., Bounche, P., Jauberteau, M.O., Dormont, D., Danton, F., Baumann, N. and Brunet, P. (1992) Frequency of central lesion in polyneuropathy associated with IgM monoclonal gammopathy: An MRI, neurophysiological and immunochemical study. Journal of Neurology, Neurosurgery & Psychiatry, 55, 112-115.

[15]   Barbieri, S., Nobile-Orazio, E., Baldini, L., Fayoumi, Z., Manfredini, KE. and Scarlato, G. (1997) Visual evoked potentials with neuropathy and macroglobulinemia. Annals of Neurology, 22, 663-666.

[16]   Quarles, R.H. (2007) Myelin-associated glycoprotein (MAG): Past, present and beyond. Journal of Neurochemistry, 100, 1431-1438.

[17]   Fluri, F., Ferracin, F., Beat, E. and Steck, A.J. (2003) Microheterogeneity of anti-myelin-associated glycoprotein antibodies. Journal of the Neurological Sciences, 207, 43-49. http://dx.doi.org/10.1016/S0022-510X(02)00359-3

[18]   Di Trapani, G., Carnevale, A., Cioffi, R.P., Massaro, A.R. and Profice, P. (1996) Multiple Sclerosis associated with peripheral demyelinating neuropathy. Clinical Neuropathology, 15, 135-138.

[19]   Drulovic, D.S., Levic, Z., Stoiasavljevic, N., Trikic, R., Cvetkovic, D. and Apostolski, S. (1998) Unusual association of multiple sclerosis and tomaculous neuropathy. Journal of the Neurological Sciences, 157, 217-222.

[20]   Falcone, M., Scalise, A., Minisci, C., Romito, D., Cancelli, I. and Gigli, G.L. (2006) Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polineuropathy. Neurological Sciences, 27, 58-62.

[21]   Pirko, I., Kuntz, N.L., Patterson, M., Keegan, B.M., Weinshenker, B.G. and Rodriguez, M. (2003) Contrasting effects of INF beta and IVIG in children with central and peripheral demyelination. Neurology, 60, 1697-1699.

[22]   Pogorzelski, R., Baniukiewicz, E. and Drozdowski, W. (2004) Subclinical lesions of peripheral nervous system in multiple sclerosis patients. Neurologia i Neurochirurgia Polska, 38, 257-264.

[23]   Quan, D., Pelak, V., Tanabe, J., Duraira, V. and Kleinschmidt-Demasters, B.K. (2005) Spinal and cranial hypertrophic neuropathy in multiple sclerosis. Muscle Nerve, 31, 772-779. http://dx.doi.org/10.1002/mus.20312

[24]   Roy, Y.I., Alexander, C.B. and Oh, S.J. (1983) Multiple sclerosis and hypertrophic demyelinating peripheral neuropathy. Muscle Nerve, 6, 312-316.

[25]   Tachi, N., Ishikawa, Y., Tsuzuki, A., Minami, R., Sasaki, K. and Shinoda, M. (1985) A case of childhood multiple sclerosis with peripheral neuropathy. Neuropediatrics, 16, 231-234. http://dx.doi.org/10.1055/s-2008-1059543

[26]   Laura, M., Leong, W., Murray, M.F., Ingle, G., Miszkiel, K.A., Altmann, D.R., Miller, D.H. and Reilly, M.M. (2005) Chronic inflammatory demyelinating polyradiculoneuropathy: MRI study of brain and spinal cord. Neurology, 64, 914-916.

[27]   Nadkarni, N. and Lisak, R.P. (1993) GuillanBarrè syndrome (GBS) with bilateral optic neuritis and central white matter disease. Neurology, 43, 843-842.

[28]   Pinedda, A.A., Ogata, K., Osoegawa, M., Murai, H., Shigeto, H., Yoshiura, T., Tobimatsu, S. and Kira, J. (2007) A distinct subgroup of chronic inflammatory demyelinating polineuropathy with CNS demyelination and favoreble response to immunotherapy. Journal of the Neurological Sciences, 255, 1-6.

[29]   de Lau, L.M.I. and Breteler, M.M.B. (2006) Epidemiology of Parkinson’s disease. The Lancet Neurology, 5, 525-535.

[30]   Mariotti, C., Gellero, C., Rimoldi, M., Mineri, R., Uziel, G., Zorzi, G., Pareyson, D., Piccolo, G., Gambi, D., Piacentini, S., Squitieri, F., Capra, R., Castelletti, B. and Di Donato, S. (2004) Ataxia with isolatedvit. Edeficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurological Sciences, 25, 130-137.

[31]   Dispenzieri, A. and Kyle, R.A. (2005) Neurological aspects of multiple myeloma and related disorders. Best Practice & Research Clinical Haematology, 18, 673-688.

[32]   Bida, J.P, Kyle, R.A., Therneau, T.M., et al. (2009) Disease associations with monoclonal gammopathy of undetermined significance: A population-based study of 17.398 patients. Mayo Clinic Proceedings, 84, 685-693.